• Revenue: XOMA recorded total revenues of $1.8 million for Q4 and $4.8 million for the full year of 2023.

• Net Loss: The company reported a net loss of $20.1 million for Q4 and $40.8 million for the full year.

• Cash Position: As of December 31, 2023, XOMA had cash and cash equivalents of $159.6 million.

• Impairment Charges: XOMA recorded $15.8 million in impairment charges due to discontinued operations and terminated agreements.

• Upcoming Events: Potential FDA action dates for tovorafenib and arimoclomol NDAs in 2024 could impact future revenues.

• Stock Repurchase Program: XOMA announced a stock repurchase program of up to $50 million through January 2027.

• Acquisitions: XOMA acquired economic interest in DSUVIA and announced the intention to acquire Kinnate Biopharma.

• Warning! GuruFocus has detected 6 Warning Signs with XOMA.

On March 8, 2024, XOMA Corp (NASDAQ:XOMA) released its 8-K filing, detailing the financial results for the fourth quarter and full year of 2023. XOMA, a biotechnology royalty aggregator, is known for acquiring future economic rights associated with pre-commercial therapeutic candidates, providing non-dilutive funding to biotech companies for their internal drug development or general corporate purposes.

Financial Performance and Challenges

XOMA's total revenues for the fourth quarter of 2023 were $1.8 million, with full-year revenues reaching $4.8 million. This represents a decrease from the $6.0 million reported in 2022, primarily due to lower milestone payments received from partners. The company's net loss widened significantly to $20.1 million for the fourth quarter and $40.8 million for the full year, compared to $6.0 million and $17.1 million, respectively, in the previous year. This increase in net loss was partly due to one-time arbitration settlement costs of $4.1 million and impairment charges totaling $15.8 million.

Despite these challenges, XOMA's financial achievements include raising up to $140 million through a royalty-backed loan related to VABYSMO sales and receiving $15.5 million in cash payments from royalties and milestone achievements in 2023. These achievements are crucial for XOMA as they provide the company with the necessary capital to fund operations and invest in new opportunities without diluting shareholder value.

Analysis of Financial Statements

General and administrative expenses for the full year of 2023 increased to $25.6 million from $23.2 million in the previous year, primarily due to a rise in stock-based compensation. XOMA's cash position is robust, with $159.6 million in cash and cash equivalents, including $6.3 million in restricted cash, as of December 31, 2023. This is a significant increase from the $57.8 million reported at the end of 2022.